Skip to main content
SpringerLink
Log in

Quinagolide in the Management of Prolactinoma

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Objective: This study reports a six year experience with quinagolide (CV205-502) in the treatment of 40 patients with hyperprolactinemia or prolactinoma. Patients and Measurements: Forty patients with hyperprolactinemia were treated with quinagolide (CV 205-502, NorprolacTM) for 2–72 months (mean 31.6 months). The patient's ages ranged from 12 to 53 years and 90% were female. Seventeen had no radiologic evidence of tumor; 11 had microadenomas; and 12 had macroadenomas. Results: All patients had a reduction of the serum prolactin following quinagolide therapy with normalization in 82% with no tumor, 73% with microadenomas, and 67% with macroadenomas. Fifty-five percent of microadenoma and 75% of macroadenoma patients had a decrease in tumor size when assessed by a blinded reviewer. Ten of 38 female patients became pregnant while taking quinagolide. The dosage of quinagolide ranged from 75 to 400 μg/day with a median dose of 100μg/day. A comparison of side effects in a subgroup of 35 patients who had taken bromocriptine prior to quinagolide administration showed a greater than 75% reduction in nausea, vomiting, dizziness, and drowsiness during quinagolide administration. Conclusions: We conclude that quinagolide is a safe and effective long-term alternative to bromocriptine therapy, particularly in those individuals with bromocriptine intolerance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bohnet HG, Dahlen HG, Wuttke W, Schneider HPG. Hyperprolactinemic anovulatory syndrome. J Clin Endocrinol Metab 1976;42:132–135.

    Google Scholar 

  2. Samaan NA, Leavens ME, Jesse RHJ. Serum prolactin in patients with “functionless” chromophobe adenomas before and after therapy. Acta Endocrinological (Copenh) 1977;84: 449–453.

    Google Scholar 

  3. Leavens ME, Samaan NA, Larson DL, Jesse RHJ, Byers RM. Prolactin secreting adenomas. Int J Adv Surg Oncol 1981;4:227–231.

    Google Scholar 

  4. Katz E, Adashi EY. Hyperprolactinemic disorders. Clin Obstet Gynecol 1190;33:622–639.

    Google Scholar 

  5. van der Heijden P, Rolland R, Thomas CMG, Brownell J. The effective, safety, and tolerability of CV 205-502 in hyperprolactinemic women: A 12 month study. Fertil Steril 1988;52:574–581.

    Google Scholar 

  6. Barnett P, Dawson J, Butler J, Coskeran P, Maccabe J, Mc-Gregor A. CV 205–502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clin Endocrinol 1990;33: 307–316.

    Google Scholar 

  7. Homburg R, West C, Brownell J, Jacobs H. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinemia. Clin Endocrinol 1990;32:565–571.

    Google Scholar 

  8. Serri O, Beauregard H, Lesage J, Pedneault L, Comtois R, Jilwan N, et al. Long term treatment with CV 205–502 in patients with prolactin-secreting pituitary macroadenomas. J Clin Endocrinol Metab 1990;71:682–687.

    Google Scholar 

  9. Vance ML, Lipper M, Klibanski A, Biller BMK, Samaan NA, Molitch ME. Treatment of prolactin-secreting pitiutary macroadenomas with the long-acting non-ergot, dopamine agonist CV205-502. Ann Inter Med 1990;112;668-673.

    Google Scholar 

  10. van't Verlaat J, Croughs R, Brownell J. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205–502. Clin Endocrinol 1990;33:619–624.

    Google Scholar 

  11. Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, et al. Endocrine function, psychiatric and clinical consequences in patients with mascroprokactinomas after long-term treatment with the new non-ergot dopamine agonist CV205–502. Q J Med 1991;81(295):891–906.

    Google Scholar 

  12. Crottaz B, Uske A, Reymond MJ, Rey F, Siegel RA, Brownell J, et al. Cv 205–502 treatment of macroprolactinomas. J Endocrinol Invest 1991;14:757–762.

    Google Scholar 

  13. Duranteau L, Chanson P, Lavoinne A, Horlait H, Lubetzki J, Kuhn J. Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumor size in bromocriptine-resistant prolactinomas. Clin Endocrinol 1991;34: 25–29.

    Google Scholar 

  14. Shoham Z, Homburg R, Jacobs H. CV205-502-effectiveness, tolerability, and safety over 24-month study. Fertil Steril 1991;55(3):501–506.

    Google Scholar 

  15. Svoboda T, Luger A, Knosp E, Geyer G. Treatment of prolactinoma with a new dopamine agonist. Dtsch Med Wochenschr 1991;116:1224–1227.

    Google Scholar 

  16. van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205–502 (a nonergot dopaminergic drug) in macroprolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991;72:1136–1141.

    Google Scholar 

  17. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J. et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74(3):577–584.

    Google Scholar 

  18. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Hormone Res 1992;38:84–89.

    Google Scholar 

  19. Merola B, Colao A, Panza N, Caruso E, Spaziante R, Schettini G et al. Clinical management of prolactinomas: A tenyear experience. Med Oncol Tumor Pharmocother 1992;9(2): 93–99.

    Google Scholar 

  20. Kvistborg A, Halse J, Bakke S, Bjoro T, Hansen E, Djoseland O, Brournell J, Jervell J. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh) 1993;128:301–307.

    Google Scholar 

  21. Glaser B, Nesher Y, Barziliai S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. J Reproduct Med 1994;39:449–454.

    Google Scholar 

  22. Merola B, Sarnacchiaro F, Colao A, et al. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacotherap 1994;48:167–174.

    Google Scholar 

  23. Merola B, Sarnacchiaro F, Colao A, et al. Positive response to compound CV 205–502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994;8:175–181.

    Google Scholar 

  24. Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma. Clin Endocrinol (Oxf) 1995;43:49–53.

    Google Scholar 

  25. Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Hormone Res 1995;44:222–228.

    Google Scholar 

  26. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromo criptine: Longterm efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413–420.

    Google Scholar 

  27. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82: 876–883.

    Google Scholar 

  28. Dollar J, Blackwell R. Diagnosis and management of prolactinomas. Cancer Metast Rev 1986;5:125–138.

    Google Scholar 

  29. Leavens M, McCutcheon I, Samaan N. Management of pituitary adenomas. Oncology 1992;6:69–80.

    Google Scholar 

  30. Thorner MO, Martin WH, Rogol AD. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980;51:438–445.

    Google Scholar 

  31. Thorner MO, Schrna JF, Evans WS, Rogol AD, Morris JL. MacLeod RM. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026–1033.

    Google Scholar 

  32. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Endocrine Neoplasia and Hormonal Disorders, and Departments of Diagnostic Radiology, and Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX

    Pamela Narcille Schultz, Lawrence Ginsberg, Ian Earle McCutcheon, Naguib Samaan, Milam Leavens & Robert Francis Gagel

Authors
  1. Pamela Narcille Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence Ginsberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian Earle McCutcheon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naguib Samaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Milam Leavens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Francis Gagel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schultz, P.N., Ginsberg, L., McCutcheon, I.E. et al. Quinagolide in the Management of Prolactinoma. Pituitary 3, 239–249 (2000). https://doi.org/10.1023/A:1012884214668

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012884214668

Search

Navigation